Catalys Pacific Fund, LP is Director & 10% Owner at Mineralys Therapeutics, Inc. (MLYS). They have made 1 open-market trade across 1 company since 2025, most recently 2025-11-20.
CIK 0001746274
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MLYS | 7,903,838 | $160.4M |
Shares reported on the most recent Form 4, priced at the 2025-11-21 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLYS | SELL | 2025-11-20 | 2025-11-21 | $43.35 | $43.4M | -8.2% | -11.4% | -33.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.